Explore our

In 2013, Nature Methods Method of the Year crowned single-cell sequencing as its Method of the Year and the field hasn’t looked back since. What was once impossible is now routine: profiling thousands of individual cells to uncover heterogeneity that bulk approaches simply average out.

Yet progress doesn’t mean replacement. Bulk sequencing still delivers robust, cost-effective insights at scale, while single-cell methods reveal the cellular players driving disease. The real power lies not in choosing one over the other, but in understanding when, and how, to use both.

Discover how explainable AI helps scientists move beyond black-box predictions to uncover the why behind biological insights. Learn how BioLizard’s Bio|Mx platform combines transparency, AI, and human expertise to drive smarter, data-informed R&D decisions.

Discover how AI is revolutionizing single cell sequencing and multi-omics research. Learn how BioLizard’s Bio|Mx platform blends AI innovation with human expertise to unlock deeper biological insights, accelerate drug discovery, and advance precision medicine.

Explore the potential and challenges of AI in drug discovery. BioLizard highlights the importance of high-quality data, human-AI collaboration, and tailored strategies to transform complex biomedical data into actionable insights for more efficient and effective R&D.

Spatial transcriptomics is emerging as a key trend in single cell sequencing, offering powerful insights into tissue biology and tumor microenvironments. Despite challenges in cost, complexity, and analytics, growing standardization will drive adoption. BioLizard already leads in expert analysis.

The rise of atlases and public single cell datasets is transforming research by reducing costs, accelerating hypothesis generation, and enriching proprietary data. With expert integration, these resources enable faster target discovery, model selection, and data-driven decisions.

High-throughput single cell sequencing enables millions of cells to be analyzed in parallel at lower cost, boosting large-scale screening, diagnostics, and rare disease research. With expert analytics, it drives robust insights, but strategic planning is essential for success.

Multi-omics is shaping the future of biomedicine, fueled by new technologies, machine learning, richer datasets, and clinical integration. As data grows in scale and diversity, AI-powered platforms like BioLizard’s Bio|Mx will drive discovery, precision medicine, and better decision-making.

Multi-omics offers deep biological insight, but success depends on smart planning, platform choice, quality control, proper integration, and powerful visualization. With expert guidance and tools like Bio|Mx, your data can fuel discovery and drive impactful decisions.

Multi-omics reveals what single omics can’t: uncovering deeper biological interactions, boosting prediction power, and accelerating discovery. From chronic disease insights to target validation using public data, BioLizard turns complex datasets into actionable breakthroughs.